Ground Truths • 7742 implied HN points • 24 Sep 23
- The expanding GLP-1 drug family shows potential for treating obesity with new triple agonist drugs.
- Clinical trials with G-agonists reveal reductions in major cardiovascular events and heart failure symptoms.
- GLP-1 drugs have shown promise in treating early type 1 diabetes, cognitive function, alcohol use disorder, and more.